---All---
  • ---All---
  • Accession
  • Catalog #

27Kip1-T157 Antibody Blocking peptideSynthetic peptide

Country
United States
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others
Ordering Information
Catalog # Size Availability Price  
BP10418a 0.1 mg 400 ul In Stock $ 45.00 Add to cart
  • Specification
  • Citiations : 0
  • Reviews
  • Protocols
  • Backgrounds

27Kip1-T157 Antibody Blocking peptide - Product info

Primary AccessionP46527
Other AccessionNP_004055.1
Clone Names4110562
Calculated MW22073 Da

27Kip1-T157 Antibody Blocking peptide - Additional info

Gene ID 1027
Format
Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.
Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.
Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

27Kip1-T157 Antibody Blocking peptide - Protein Information

Name CDKN1B
Synonyms KIP1
Function
Important regulator of cell cycle progression. Involved in G1 arrest. Potent inhibitor of cyclin E- and cyclin A-CDK2 complexes. Forms a complex with cyclin type D-CDK4 complexes and is involved in the assembly, stability, and modulation of CCND1- CDK4 complex activation. Acts either as an inhibitor or an activator of cyclin type D-CDK4 complexes depending on its phosphorylation state and/or stoichometry
Cellular Location
Nucleus. Cytoplasm. Endosome (By similarity). Note=Nuclear and cytoplasmic in quiescent cells. AKT- or RSK-mediated phosphorylation on Thr-198, binds 14-3-3, translocates to the cytoplasm and promotes cell cycle progression Mitogen-activated UHMK1 phosphorylation on Ser-10 also results in translocation to the cytoplasm and cell cycle progression Phosphorylation on Ser-10 facilitates nuclear export. Translocates to the nucleus on phosphorylation of Tyr-88 and Tyr-89 Colocalizes at the endosome with SNX6; this leads to lysosomal degradation (By similarity)
Tissue Location
Expressed in all tissues tested. Highest levels in skeletal muscle, lowest in liver and kidney

27Kip1-T157 Antibody Blocking peptide - Related products

AP10418a: 27Kip1-T157 Antibody

AP10431a: Cofilin (Ser3) antibody

AP13302b: CDKN1B Antibody (C-term)

AP2905a: CFL1 Antibody (N-term)

AP2905c: CFL1 Antibody (Center)

AP3191a: Phospho-p27Kip1-S10 Antibody

AP3192a: Phospho-p27Kip1-S178 Antibody

AP3193a: Phospho-p27Kip1-T157 Antibody

AP3194a: Phospho-p27Kip1-T187 Antibody

AP3529a: Phospho-p27Kip1-T198 Antibody

AP3751a: Phospho-Cofilin- Ser3 antibody

AP6269b: 27Kip1 Antibody (C-term)

RI11025: CFL1 predesign siRNA

BP10418a: 27Kip1-T157 Antibody Blocking peptide

BP10431a: Cofilin (Ser3) antibody Blocking peptide

BP2905a: CFL1 Antibody (N-term) Blocking Peptide

BP2905c: CFL1 Antibody (Center) Blocking Peptide

BP3191a: Phospho-p27Kip1-S10 Antibody Blocking Peptide

BP3192a: Phospho-p27Kip1-S178 Antibody Blocking Peptide

BP3193a: Phospho-p27Kip1-T157 Antibody Blocking Peptide

BP3194a: Phospho-p27Kip1-T187 Antibody Blocking Peptide

BP3529a: Phospho-p27Kip1-T198 Antibody Blocking Peptide

BP6269b: 27Kip1 Antibody (C-term) Blocking Peptide

AT1506a: CFL1 Antibody (monoclonal) (M04)

AO1379a: CDKN1B Antibody

AJ1569c: p27/Kip1 Antibody (C-term)

AJ1569d: p27/Kip1 Antibody Phospho (pS10)

AE1009a: Cofilin Antibody (S3)

AE1009b: Phospho-Cofilin-S3 Antibody

Abgent welcomes feedback from its customers.

If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.

If you have any additional inquiries please email technical services at tech@abgent.com.

Thank you for your support.


Submit

Provided below are standard protocols that you may find useful for product applications.

BACKGROUND

This gene encodes a cyclin-dependent kinase inhibitor,which shares a limited similarity with CDK inhibitor CDKN1A/p21.The encoded protein binds to and prevents the activation of cyclinE-CDK2 or cyclin D-CDK4 complexes, and thus controls the cell cycleprogression at G1. The degradation of this protein, which istriggered by its CDK dependent phosphorylation and subsequentubiquitination by SCF complexes, is required for the cellulartransition from quiescence to the proliferative state. [provided byRefSeq].

REFERENCES

Kajihara, R., et al. Biochem. Biophys. Res. Commun. 401(3):350-355(2010)Kedde, M., et al. Nat. Cell Biol. 12(10):1014-1020(2010)Canbay, E., et al. Anticancer Res. 30(7):3093-3098(2010)Do Nascimento Borges, B., et al. In Vivo 24(4):579-582(2010)Qin, J., et al. Hepatogastroenterology 57 (99-100), 547-553 (2010) :